2025-09-09 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the data you provided, presented in English with a focus on key figures and succinct interpretations.

**Report on TransMedics Group Inc. (TMDX)**

**Company Overview:** TransMedics Group Inc. is a medical technology company focused on preserving organs for transplantation.

**1. Performance vs. S&P 500 (VOO)**

*   **TMDX Cumulative Return:** 202.64%
*   **VOO Cumulative Return:** 70.45%
*   **Absolute Divergence (Current):** 129.8
*   **Relative Divergence (Current):** 53.8 (This places the current divergence in the upper-middle range of its historical fluctuation relative to VOO).

**Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD    | Alpha   | Beta | Cap(B) |
|------------|---------|--------|---------|------|--------|
| 2019-2021  | -4.0%  | 63.4%  | -50.0% | -0.0 | 0.7    |
| 2020-2022  | 140.0%  | 68.3%  | 138.0% | -0.0 | 2.1    |
| 2021-2023  | 95.0%   | 69.4%  | 78.0%  | 0.1  | 2.7    |
| 2022-2024  | 147.0%  | 82.8%  | 122.0% | 0.1  | 2.2    |
| 2023-2025  | 84.0%   | 82.8%  | 32.0%  | 0.4  | 3.6    |

*   **Analysis:** TMDX has significantly outperformed the S&P 500, resulting in high alpha figures. The Beta, however, stays low (0-0.4). The MDD shows high volatility.

**2. Recent Price Action**

*   **Current Price:** 104.01
*   **Last Market Data:** Price: 105.58, Previous Close: 104.01, Change: 1.51 (slight increase)
*   **5-Day Moving Average:** 107.76
*   **20-Day Moving Average:** 118.71
*   **60-Day Moving Average:** 121.04

*   **Analysis:** The price is below all three moving averages, indicating a potential downtrend in the short to medium term. The recent minor price increase to $105.58 shows a small reversal.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 11.33 (Oversold)
*   **PPO:** -1.74 (Bearish)
*   **Hybrid Signal:** cash_60%_Sell 0.1% of holdings
*   **20-Day Relative Divergence Change:** -4.2 (Short-term decrease)
*   **Expected Return:** 83.6% (Long-term, relative to S&P 500)

*   **Analysis:**  The RSI indicates the stock is oversold, which *could* suggest a potential bounce. The PPO is bearish. The negative change in relative divergence suggests recent underperformance. The high expected return suggests strong confidence in long-term prospects. The MRI indicates low market risk.

**4. Recent News & Significant Events**

*   **[2025-09-04] Stifel Initiates TransMedics Group at Neutral With $115 Price Target:** A neutral rating could indicate a period of stabilization.
*   **[2025-08-29] Reasons to Retain TransMedics Stock in Your Portfolio for Now (Zacks):** This suggests a hold strategy is currently reasonable.
*   **[2025-08-29] Why Is TransMedics (TMDX) Down 1.9% Since Last Earnings Report? (Zacks):** Analyzing the reasons for the drop is crucial (potential overreaction, market conditions).
*   **[2025-08-28] What TransMedics Group (TMDX)'s Upward 2025 Earnings Revisions Mean For Shareholders (Simply Wall St.):** Positive earnings revisions are a good sign for future performance.
*   **[2025-08-25] TransMedics to Present at Upcoming September Investor Conferences (PR Newswire):** This could lead to increased awareness and potential investor interest.
*   **[2025-08-25] Terumo to buy OrganOx for $1.5B to enter transplant field (MedTech Dive):** Increased investment and competition in the organ preservation field.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (1.78)
*   **Opinions:** 8
*   **Target Price (Avg/High/Low):** 138.88 / 170.00 / 114.00

*   **Analysis:** Analyst consensus leans towards a "Buy" rating, with a target price significantly higher than the current price, suggesting potential upside.

**5. Recent Earnings Analysis**

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

*   **Analysis:** The company has consistently exceeded EPS expectations in recent quarters except 2024-10-28.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | $0.16B   | 61.38%       |
| 2025-03-31   | $0.14B   | 61.47%       |
| 2024-12-31   | $0.12B   | 59.21%       |
| 2024-09-30   | $0.11B   | 55.94%       |
| 2024-06-30   | $0.11B   | 60.59%       |

**Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|----------|---------|
| 2025-06-30   | $0.32B   | 10.97%  |
| 2025-03-31   | $0.27B   | 9.64%   |
| 2024-12-31   | $0.23B   | 3.00%   |
| 2024-09-30   | $0.21B   | 2.01%   |
| 2024-06-30   | $0.19B   | 6.42%   |

*   **Analysis:** Revenue is growing steadily, and profit margins are consistently high, indicating strong financial health. ROE is increasing, suggesting improved profitability relative to equity.

**7. Overall Summary & Conclusion**

TransMedics Group Inc. (TMDX) shows a complex picture. It has significantly outperformed the S&P 500 historically, demonstrated by its high Alpha and overall cumulative return. The company exhibits strong revenue growth, high profit margins, and a "Buy" analyst consensus with a target price significantly above the current level. Recent earnings have consistently exceeded expectations.

However, there are short-term concerns. The stock price is below its moving averages, the RSI indicates an oversold condition, and the PPO is bearish, suggesting a potential correction. Recent news indicates a neutral rating from Stifel, although there is still a consensus to retain TransMedics.

**Overall:** TMDX appears to be a company with strong long-term potential, but recent price action suggests caution in the short term. Investors should weigh the positive long-term outlook against the current technical indicators and consider that the stock may be experiencing a pullback. Further investigation into the reasons for the recent price decline and potential impact of increased competition in the organ preservation field is warranted.
